Skip to main content

Dr. Bess Flashner, MD

Pulmonology (Pulmonary Disease Physician)

  • Medicare participating

At a glance

Years since graduation
11
In the NPI registry since
2015
Medicare patients seen, 2024
265

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is

Education and training

  • 2015Medical school: George Washington University School of Medicine
  • 2015Registered with an NPI (national billing number; not a license date)

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Pulmonary Disease Physician primary
    MA license 278924
  • Internal Medicine Physician
    MA license 264176

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Pulmonology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
265
Services billed
661
Patients’ average age
75
Most frequent Medicare services, 2023
ServiceTimesPatients
Test to measure expiratory airflow and volume199197
Established patient office or other outpatient visit, 40-54 minutes17399
Critical care, first 30-74 minutes15375
Test to examine how well the lungs exchange gases9694
New patient office or other outpatient visit, 60-74 minutes5151
Test to measure expiratory airflow and volume changes before and after medication administration2323
Test to determine lung volumes using gas dilution or washout2323
Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes2217
Test to determine lung volumes using sensors1818
Critical care, each additional 30 minutes1511

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Most prescribed drugs, Medicare Part D 2024
DrugPrescriptions
Trelegy Ellipta (fluticasone/umeclidin/vilanter)
Other prescribers in Boston, MA
154
Ofev (nintedanib esylate)84
Prednisone
Other prescribers in Boston, MA
64
Albuterol Sulfate Hfa (albuterol sulfate)
Other prescribers in Boston, MA
45
Wixela Inhub (fluticasone propion/salmeterol)
Other prescribers in Boston, MA
45
Breztri Aerosphere (budesonide/glycopyr/formoterol)
Other prescribers in Boston, MA
38
Pirfenidone31
Anoro Ellipta (umeclidinium brm/vilanterol tr)
Other prescribers in Boston, MA
30
Mycophenolate Mofetil
Other prescribers in Boston, MA
29
Stiolto Respimat (tiotropium br/olodaterol hcl)
Other prescribers in Boston, MA
27

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 1 companies reported 2 payments worth $3,778 in total to this clinician.

By type
Consulting Fee$3,690
Travel and Lodging$88.07

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Jan 7, 2025Boehringer Ingelheim Pharmaceuticals, Inc.
Jan 7, 2025
Consulting Fee$3,690
Jan 7, 2025Boehringer Ingelheim Pharmaceuticals, Inc.
Jan 7, 2025
Travel and Lodging
travel to Boston, MA · in-kind
$88.07

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Massachusetts →

Industry-funded research

Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $35,142 in research payments for these studies, mostly to the institutions running them.

  • An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON)
    Boehringer Ingelheim Pharmaceuticals, Inc.
  • An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON)
    Boehringer Ingelheim International GmbH

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Pulmonology clinicians in Boston

Sources

NPI registry (CMS NPPES, November 2026; record last updated October 19, 2022), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1588044382. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.